Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose Escalation, and Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral WP1122 in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)

NCT05365321 is registered in ClinicalTrials.gov with Andrei Carvalho Sposito as lead sponsor.

NCT NCT05365321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05365321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose Escalation, and Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral WP1122 in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)
Lead sponsor
Andrei Carvalho Sposito
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 31, 2022
Completion date
October 31, 2023
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 acute respiratory distress syndrome, mechanical ventilation complication